AbTis and ChemExpress in China sign MOU for next-generation 바카라 토토 사이트 therapeutics development

[by Lee, Young Sung] AbTis, a company specializing in 바카라 토토 사이트 therapeutics development, announced on May 13 that it has signed a Toolbox partnership business agreement (MOU) with ChemExpress, a Shanghai-based 바카라 토토 사이트 contract development and manufacturing organization (CDMO).

The Toolbox partnership is an integrated 바카라 토토 사이트 that seamlessly combines different technologies and solutions, allowing customers to select and utilize services tailored to their specific needs.

AbTis aims to enhance the safety and efficacy of 바카라 토토 사이트s compared to existing technologies through its proprietary location-selective antibody conjugation platform, 'AbClick®’. ChemExpress, a specialized CDMO in the 바카라 토토 사이트 sector, offers a comprehensive one-stop platform capable of supporting the entire process from research and development to GMP production.

Through this agreement, AbTis and ChemExpress will integrate their respective 바카라 토토 사이트 research and development capabilities, leveraging their combined global networks to attract new customers, expand into new markets, and deliver innovative and efficient solutions to customers.

In particular, the two companies plan to extend their collaboration beyond the AppClick platform, integrating their core strengths in antibody conjugation technology and industrialization to jointly advance the development of next-generation 바카라 토토 사이트s.

Through this collaboration, the companies aim to enhance the competitiveness of the global 바카라 토토 사이트 industry and generate sustainable value for human health by providing innovative therapies to patients more rapidly.

“ChemExpress is one of the pioneering companies in 바카라 토토 사이트 research in China, with strong technological capabilities and a highly skilled talent pool,” expressed Han Tae-dong, CEO of AbTis. “By integrating the AbClick technology platform and ChemExpress’ strengths, we aim to further expand the application of position-selective antibody conjugation technology, ultimately contributing to the delivery of safer and more effective precision treatments for patients.”

“We are very pleased to enter into this strategic agreement with AbTis, which possesses the third-generation antibody conjugation technology platform AbClick,” stated Zheng Baofu, Chairman of ChemExpress. “Through this collaboration, we aim to maximize the combined strengths of both companies, accelerating the development of 바카라 토토 사이트 and bioconjugate novel drugs and providing benefits to patients worldwide more rapidly,” he added.